Tag: statin

News

06/15/25

Statin use linked to lower breast cancer-specific mortality

Studies

• Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics Cite
  Scott OW, Tin Tin S, Cavadino A, Elwood JM. Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics. British Journal of Cancer. Springer Science and Business Media LLC; 2025; 10.1038/s41416-025-03070-w
• Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial Cite
  Maurer C, Agostinetto E, Ameye L, Lambertini M, Martel S, Ponde N, et al. Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2025; 10.1007/s10549-025-07699-2
• Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study Cite
  Skriver C, Cronin-Fenton D, Borgquist S, Hansen Viuff J, Alkner S, Rydén L, et al. Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study. British Journal of Cancer. Springer Science and Business Media LLC; 2025; 10.1038/s41416-025-02974-x
• Statins as Secondary Preventive Agent to Limit Breast Cancer Metastatic Outgrowth Cite
  Atale N, Wells A. Statins as Secondary Preventive Agent to Limit Breast Cancer Metastatic Outgrowth. International Journal of Molecular Sciences. MDPI AG; 2025; 26:1300 10.3390/ijms26031300
• The role of statins in breast cancer survivors Cite
  Bashey SZ, Kordon A, Ositelu K, Rao A, Akhter N. The role of statins in breast cancer survivors. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2025; 210:1-10 10.1007/s10549-024-07605-2
• Association between GPX4 and HMGCR gene expression and cell proliferation in atypical hyperplasia of the breast Cite
  Coradini D. Association between GPX4 and HMGCR gene expression and cell proliferation in atypical hyperplasia of the breast. Exploration of Medicine. Open Exploration Publishing; 2024; 5:950-959 10.37349/emed.2024.00268
• Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer Cite
  Hillis AL, Martin TD, Manchester HE, Högström J, Zhang N, Lecky E, et al. Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2024; 10.1158/0008-5472.can-24-0970
• Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial Cite
  Kettana KM, El‑Haggar SM, Alm El-Din MA, El‑Afify DR. Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial. Medical Oncology. Springer Science and Business Media LLC; 2024; 41 10.1007/s12032-024-02426-1
• Statins in breast cancer treatment and management: a mini-review of potential benefits and clinical implications Cite
  Aftab A, Hussain T, Hussain R, Shah HH, Habiba U, Haque MA. Statins in breast cancer treatment and management: a mini-review of potential benefits and clinical implications. International Journal of Surgery: Global Health. Ovid Technologies (Wolters Kluwer Health); 2024; 7 10.1097/gh9.0000000000000461
• Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression Cite
  Park JH, Mortaja M, Son HG, Zhao X, Sloat LM, Azin M, et al. Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression. Nature Communications. Springer Science and Business Media LLC; 2024; 15 10.1038/s41467-024-48441-8
• Statin use is associated with a lower risk of all-cause death in patients with breast cancer treated with anthracycline containing regimens: a global federated health database analysis Cite
  Bucci T, Gue Y, Dobson R, Palmieri C, Pignatelli P, Lip GYH. Statin use is associated with a lower risk of all-cause death in patients with breast cancer treated with anthracycline containing regimens: a global federated health database analysis. Clinical and Experimental Medicine. Springer Science and Business Media LLC; 2024; 24 10.1007/s10238-024-01395-z
• Statin use and risks of breast cancer recurrence and mortality Cite
  Guo H, Malone KE, Heckbert SR, Li CI. Statin use and risks of breast cancer recurrence and mortality. Cancer. Wiley; 2024; 10.1002/cncr.35362
• Post-surgery statin use contributes to favorable outcomes in patients with early breast cancer Cite
  Giorello MB, Marks MP, Osinalde TM, Padin MdR, Wernicke A, Calvo JC, et al. Post-surgery statin use contributes to favorable outcomes in patients with early breast cancer. Cancer Epidemiology. Elsevier BV; 2024; 90:102573 10.1016/j.canep.2024.102573
• Regulating Cholesterol in Tumorigenesis: A Novel Paradigm for Tumor Nanotherapeutics Cite
  Wu H, Wu X, Zhao M, Yan J, Li C, Zhang Z, et al. Regulating Cholesterol in Tumorigenesis: A Novel Paradigm for Tumor Nanotherapeutics. International Journal of Nanomedicine. Informa UK Limited; 2024; Volume 19:1055-1076 10.2147/ijn.s439828
• Concurrent Use of Statins in Patients Undergoing Curative Intent Treatment for Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis Cite
  McKechnie T, Brown Z, Lovrics O, Yang S, Kazi T, Eskicioglu C, et al. Concurrent Use of Statins in Patients Undergoing Curative Intent Treatment for Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis. Clinical Breast Cancer. Elsevier BV; 2023; 10.1016/j.clbc.2023.12.001
• Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer Cite
  Hillis AL, Martin TD, Manchester HE, Hogstrom JM, Zhang N, Lecky E, et al. Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer. Cold Spring Harbor Laboratory; 2024; 10.1101/2024.01.16.575899
• Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer Cite
  Li L, Wang H, Zhang S, Gao S, Lu X, Pan Y, et al. Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer. International Journal of Surgery. Ovid Technologies (Wolters Kluwer Health); 2024; 10.1097/js9.0000000000001582
• PP171 Therapeutic influence of simvastatin on MCF-7 and MDA-MB-231 breast cancer cells via mitochondrial depletion and improvement in chemosensitivity of cytotoxic drugs Cite
  Parmar HS. PP171 Therapeutic influence of simvastatin on MCF-7 and MDA-MB-231 breast cancer cells via mitochondrial depletion and improvement in chemosensitivity of cytotoxic drugs. ESMO Open. Elsevier BV; 2023; 8:102166 10.1016/j.esmoop.2023.102166
• Fluvastatin prevents lung metastasis in triple-negative breast cancer by triggering autophagy via the RhoB/PI3K/mTOR pathway Cite
  Xu W, Zhang T, Zhou Y, Mao Y. Fluvastatin prevents lung metastasis in triple-negative breast cancer by triggering autophagy via the RhoB/PI3K/mTOR pathway. Experimental Cell Research. Elsevier BV; 2023;:113893 10.1016/j.yexcr.2023.113893
• Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines Cite
  Bodgi L, Bou-Gharios J, Azzi J, Challita R, Feghaly C, Baalbaki K, et al. Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines. Pharmacological Reports. Springer Science and Business Media LLC; 2023; 10.1007/s43440-023-00560-7
• Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer Cite
  Murto MO, Simolin N, Arponen O, Siltari A, Artama M, Visvanathan K, et al. Statin Use, Cholesterol Level, and Mortality Among Females With Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2343861 10.1001/jamanetworkopen.2023.43861
• Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis Cite
  Bucci T, Gue Y, Dobson R, Palmieri C, Pignatelli P, Cross M, et al. Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis. European Heart Journal. Oxford University Press (OUP); 2023; 44 10.1093/eurheartj/ehad655.2876
• Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study Cite
  Löfling LL, Støer NC, Andreassen BK, Ursin G, Botteri E. Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01697-2
• Repurposing Two Old Friends to Fight Cancer: Caffeine and Statins Cite
  Stouth DW, Lebeau PF, Austin RC. Repurposing Two Old Friends to Fight Cancer: Caffeine and Statins. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:2091-2092 10.1158/0008-5472.can-23-1066
• Association of statin use and increase in lipoprotein(a): a real-world database research Cite
  Feng T, Li Y, Xue X, Yang W, Li Q, Huang Y, et al. Association of statin use and increase in lipoprotein(a): a real-world database research. European Journal of Medical Research. Springer Science and Business Media LLC; 2023; 28 10.1186/s40001-023-01155-x
• Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study Cite
  Scott OW, TinTin S, Harborg S, Kuper-Hommel MJJ, Lawrenson R, Elwood JM. Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-022-06815-w
• The Link Between Statins and Breast Cancer in Mouse Models: A Systematic Review Cite
  Watson R, Tulk A, Erdrich J. The Link Between Statins and Breast Cancer in Mouse Models: A Systematic Review. Cureus. Cureus, Inc.; 2022; 10.7759/cureus.31893
• Atorvastatin Improves Cisplatin Sensitivity Through Modulation of Cholesteryl Ester Homeostasis in Breast Cancer Cells Cite
  Santos DZd, Guimaraes IdS, Hakeem-Sanni M, Cochran B, Rye K, Grewal T, et al. Atorvastatin Improves Cisplatin Sensitivity Through Modulation of Cholesteryl Ester Homeostasis in Breast Cancer Cells. Research Square Platform LLC; 2022; 10.21203/rs.3.rs-1907209/v1
• Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells Cite
  O’Grady S, Crown J, Duffy MJ. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells. Medical Oncology. Springer Science and Business Media LLC; 2022; 39 10.1007/s12032-022-01733-9
• Statins and angiogenesis in non-cardiovascular diseases Cite
  Zahedipour F, Butler AE, Rizzo M, Sahebkar . Statins and angiogenesis in non-cardiovascular diseases. Drug Discovery Today. Elsevier BV; 2022; 10.1016/j.drudis.2022.07.005
• Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18 Cite
  Minichsdorfer C, Fuereder T, Leutner M, Singer CF, Kacerovsky-Strobl S, Egle D, et al. Abstract P1-15-01: Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P1-15-01-P1-15-01 10.1158/1538-7445.sabcs21-p1-15-01
• Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database Cite
  Kim D, Ahn HS, Kim HJ. Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33869
• Autophagy is induced and modulated by cholesterol depletion through transcription of autophagy-related genes and attenuation of flux Cite
  Shapira KE, Shapira G, Schmukler E, Pasmanik-Chor M, Shomron N, Pinkas-Kramarski R, et al. Autophagy is induced and modulated by cholesterol depletion through transcription of autophagy-related genes and attenuation of flux. Cell Death Discovery. Springer Science and Business Media LLC; 2021; 7 10.1038/s41420-021-00718-3
• Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study Cite
  Moksud N, Loo LWM, Yang J, Huang C, Haiman CA, Le Marchand L, et al. Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06360-y
• Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer Cite
  Marti JLG, Beckwitt CH, Clark AM, Wells A. Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-021-01529-0
• Association of statin use with clinical outcomes in patients with triple‐negative breast cancer Cite
  Nowakowska MK, Lei X, Thompson MT, Shaitelman SF, Wehner MR, Woodward WA, et al. Association of statin use with clinical outcomes in patients with triple‐negative breast cancer. Cancer. Wiley; 2021; 10.1002/cncr.33797
• Medication use and mammographic breast density Cite
  Han Y, Lee CT, Xu S, Mi X, Phillip CR, Salazar AS, et al. Medication use and mammographic breast density. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06321-5
• Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Hautakoski A, Marttila M, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with survival from ductal and lobular breast carcinoma in women with type 2 diabetes. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-88488-x
• Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance Cite
  Tilija Pun N, Jeong C. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance. Pharmaceuticals. MDPI AG; 2021; 14:470 10.3390/ph14050470
• Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer Cite
  Bhardwaj A, Embury MD, Rojo RD, Albarracin C, Bedrosian I. Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Research and Treatment; 2021; 10.1007/s10549-021-06229-0
• Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture Cite
  Manda K, Juerß D, Fischer P, Schröder A, Koenen A, Hildebrandt G. Simvastatin treatment varies the radiation response of human breast cells in 2D or 3D culture. Investigational New Drugs. Springer Science and Business Media LLC; 2020; 10.1007/s10637-020-01046-6
• LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies Cite
  Revilla G, Cedó L, Tondo M, Moral A, Pérez JI, Corcoy R, et al. LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Seminars in Cancer Biology. Elsevier BV; 2020; 10.1016/j.semcancer.2020.11.012
• Does adherence to lipid‐lowering medications improve cancer survival? A nationwide study of breast and colorectal cancer, and melanoma Cite
  Feng J, Qin X. Does adherence to lipid‐lowering medications improve cancer survival? A nationwide study of breast and colorectal cancer, and melanoma. British Journal of Clinical Pharmacology. Wiley; 2020; 10.1111/bcp.14573
• Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study Cite
  Lu Y, Huang D, Chen P, Tsai C, Lin M, Lin C, et al. Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05969-9
• Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity Cite
  El-Ashmawy NE, Al-Ashmawy GM, Amr EA, Khedr EG. Inhibition of lovastatin- and docosahexaenoic acid-initiated autophagy in triple negative breast cancer reverted resistance and enhanced cytotoxicity. Life Sciences. Elsevier BV; 2020; 259:118212 10.1016/j.lfs.2020.118212
• Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study Cite
  Harborg S, Heide-Jørgensen U, Ahern TP, Ewertz M, Cronin-Fenton D, Borgquist S. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 183:153-160 10.1007/s10549-020-05749-5
• Abstract P3-11-17: Statins suppress the aggressive phenotype of triple negative breast cancer cells via modulation of EGFR signalling Cite
  Smith C, Alim S, Kadi A, Lawati RA, Miles M, Hiscox S. Abstract P3-11-17: Statins suppress the aggressive phenotype of triple negative breast cancer cells via modulation of EGFR signalling. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p3-11-17
• Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study Cite
  Bjarnadottir O, Feldt M, Inasu M, Bendahl P, Elebro K, Kimbung S, et al. Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-019-57323-9
• Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer Cite
  Li YR, Ro V, Steel L, Carrigan E, Nguyen J, Williams A, et al. Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:669-677 10.1007/s10549-019-05267-z
• Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes Cite
  Hosio M, Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:741-748 10.1007/s10549-019-05185-0
• Statin use and breast cancer survival – a Swedish nationwide study Cite
  Borgquist S, Broberg P, Tojjar J, Olsson H. Statin use and breast cancer survival – a Swedish nationwide study. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-018-5263-z
• Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy Cite
  Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology. Elsevier BV; 2018; 35:153-159 10.1016/j.cjca.2018.11.028
• Statin use and risk of contralateral breast cancer: a nationwide cohort study Cite
  Langballe R, Cronin-Fenton D, Dehlendorff C, Jensen M, Ejlertsen B, Andersson M, et al. Statin use and risk of contralateral breast cancer: a nationwide cohort study. British Journal of Cancer. Springer Science and Business Media LLC; 2018; 119:1297-1305 10.1038/s41416-018-0252-1
• Therapeutic effect of simvastatin on DMBA-induced breast cancer in mice Cite
  Karimi B, Ashrafi M, Shomali T, Yektaseresht A. Therapeutic effect of simvastatin on DMBA-induced breast cancer in mice. Fundamental & Clinical Pharmacology. Wiley; 2018; 33:84-93 10.1111/fcp.12397
• Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population Cite
  Schairer C, Freedman DM, Gadalla SM, Pfeiffer RM. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:607-614 10.1007/s10549-018-4680-7
• The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells Cite
  Baek AE, Yu YA, He S, Wardell SE, Chang C, Kwon S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nature Communications. Springer Science and Business Media LLC; 2017; 8 10.1038/s41467-017-00910-z
• Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines Cite
  Karlic H, Haider F, Thaler R, Spitzer S, Klaushofer K, Varga F. Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines. International Journal of Molecular Sciences. MDPI AG; 2017; 18:1982 10.3390/ijms18091982
• The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis Cite
  Liu B, Yi Z, Guan X, Zeng Y, Ma F. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:1-11 10.1007/s10549-017-4246-0
• Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer Cite
  Kimbung S, Chang C, Bendahl P, Dubois L, Thompson JW, McDonnell DP, et al. Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. Endocrine-Related Cancer. Bioscientifica; 2017;:339-349 10.1530/erc-16-0533
• Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study Cite
  Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, et al. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1179-1188 10.1200/jco.2016.70.3116
• Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers Cite
  Henninger C, Fritz G. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death & Disease. Springer Science and Business Media LLC; 2017; 8:e2564-e2564 10.1038/cddis.2016.418
• Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency Cite
  Jung HH, Lee S, Kim J, Ahn JS, Park YH, Im Y. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep33035
• The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women Cite
  Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, et al. The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women. Cancer Prevention Research. American Association for Cancer Research (AACR); 2016; 9:379-384 10.1158/1940-6207.capr-15-0300
• Statin use and breast cancer survival: a nationwide cohort study in Scotland Cite
  Mc Menamin ÚC, Murray LJ, Hughes CM, Cardwell CR. Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2651-0
• De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I–III breast cancer Cite
  Smith A, Murphy L, Sharp L, O'Connor D, Gallagher WM, Bennett K, et al. De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I–III breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:592-598 10.1038/bjc.2016.232
• Statin use and all-cancer survival: prospective results from the Women’s Health Initiative Cite
  Wang A, Aragaki AK, Tang JY, Kurian AW, Manson JE, Chlebowski RT, et al. Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:129-135 10.1038/bjc.2016.149
• Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis Cite
  Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis. International Journal of Cancer. Wiley; 2016; 139:1281-1288 10.1002/ijc.30185
• Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats Cite
  Yang W, Zhang Q, Yang Y, Xu J, Fan A, Yang CS, et al. Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. Xenobiotica. Informa UK Limited; 2016; 47:86-92 10.3109/00498254.2016.1159747
• Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype Cite
  Guo H, Liu Y, Gu J, Wang Y, Liu L, Zhang P, et al. Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype. Cancer Immunology, Immunotherapy. Springer Science and Business Media LLC; 2016; 65:677-688 10.1007/s00262-016-1824-7
• Statin Use and Breast Cancer Risk in the Nurses' Health Study Cite
  Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, Ahern TP. Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2016; 25:201-206 10.1158/1055-9965.epi-15-0654
• Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer Cite
  Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K. Weight Change in Breast Cancer Survivors Compared to Cancer-Free Women: A Prospective Study in Women at Familial Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2015; 24:1262-1269 10.1158/1055-9965.epi-15-0212
• Chronic heart damage following doxorubicin treatment is alleviated by lovastatin Cite
  Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacological Research. Elsevier BV; 2015; 91:47-56 10.1016/j.phrs.2014.11.003
• Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland Cite
  Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E. Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e110231 10.1371/journal.pone.0110231
• Statin Use After Diagnosis of Breast Cancer and Survival Cite
  Cardwell CR, Hicks BM, Hughes C, Murray LJ. Statin Use After Diagnosis of Breast Cancer and Survival. Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2015; 26:68-78 10.1097/ede.0000000000000189
• Statins and breast cancer prognosis: evidence and opportunities Cite
  Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. The Lancet Oncology. Elsevier BV; 2014; 15:e461-e468 10.1016/s1470-2045(14)70119-6
• Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort Cite
  Nickels S, Vrieling A, Seibold P, Heinz J, Obi N, Flesch-Janys D, et al. Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort. PLoS ONE. Public Library of Science (PLoS); 2013; 8:e75088 10.1371/journal.pone.0075088
• Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway Cite
  Park YH, Jung HH, Ahn JS, Im Y. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochemical and Biophysical Research Communications. Elsevier BV; 2013; 439:275-279 10.1016/j.bbrc.2013.08.043
• Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age Cite
  McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI. Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:1529-1537 10.1158/1055-9965.epi-13-0414
• Statin use in primary inflammatory breast cancer: a cohort study Cite
  Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, et al. Statin use in primary inflammatory breast cancer: a cohort study. British Journal of Cancer. Springer Science and Business Media LLC; 2013; 109:318-324 10.1038/bjc.2013.342
• Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol Cite
  Gopalan A, Yu W, Sanders BG, Kline K. Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol. Cancer Letters. Elsevier BV; 2013; 328:285-296 10.1016/j.canlet.2012.10.003
• The statin-low cholesterol-cancer conundrum Cite
  Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum. QJM. Oxford University Press (OUP); 2011; 105:383-388 10.1093/qjmed/hcr243
• Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway Cite
  Freed-Pastor W, Mizuno H, Zhao X, Langerød A, Moon S, Rodriguez-Barrueco R, et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell. Elsevier BV; 2012; 148:244-258 10.1016/j.cell.2011.12.017
• Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study Cite
  Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1461-1468 10.1093/jnci/djr291
• Digoxin Use and the Risk of Breast Cancer in Women Cite
  Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M. Digoxin Use and the Risk of Breast Cancer in Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:2165-2170 10.1200/jco.2010.32.8146
• Role of Cholesterol in the Development and Progression of Breast Cancer Cite
  Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, et al. Role of Cholesterol in the Development and Progression of Breast Cancer. The American Journal of Pathology. Elsevier BV; 2011; 178:402-412 10.1016/j.ajpath.2010.11.005
• Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions Cite
  Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions. Endocrine Reviews. The Endocrine Society; 2008; 30:51-74 10.1210/er.2008-0022
• 3-(4′-Hydroxyl-3′,5′-dimethoxyphenyl)propionic Acid, an Active Principle of Kimchi, Inhibits Development of Atherosclerosis in Rabbits Cite
  Kim HJ, Lee JS, Chung HY, Song SH, Suh H, Noh JS, et al. 3-(4′-Hydroxyl-3′,5′-dimethoxyphenyl)propionic Acid, an Active Principle of Kimchi, Inhibits Development of Atherosclerosis in Rabbits. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2007; 55:10486-10492 10.1021/jf072454m